Clinical Trials Sponsored by A&G Pharmaceutical Inc.

Total 152 results

A&G Pharmaceutical Inc.
University of Maryland Greenebaum Cancer Center

Recruiting

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Non Small Cell Lung Cancer | Mesothelioma | Triple Negative Breast Cancer | Hormone-Resistant Breast Cancer

United States
University of Maryland, Baltimore
A&G Pharmaceutical

Terminated

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer (1380GCC)

Healthy Volunteers

United States
Eupraxia Pharmaceuticals Inc.
NBCD A/S

Completed

Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

Osteoarthritis, Knee

Poland, Czechia, Denmark
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban (PER977-P1)

Anticoagulant Reversal | Reversal of Edoxaban Induced Anticoagulation

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Recruiting

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin (PER977)

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...

Completed

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

Healthy

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

Anticoagulation Reversal

United States
Perosphere Pharmaceuticals Inc, a wholly owned...
Quintiles, Inc.

Completed

Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants

Healthy
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD (PHYOX7)

End Stage Renal Disease | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1

Germany, Spain, United States, United Kingdom, Italy, United Arab Emirates, Lebanon, Morocco, France, Romania
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Active, not recruiting

A Study of Belcesiran in Patients With AATLD (ESTRELLA)

Alpha 1-Antitrypsin Deficiency

United Kingdom, United States, Ireland, Belgium, New Zealand, Spain, Netherlands, Portugal, Canada, Australia, France, Austria, Germany, Sweden
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (PHYOX8)

Primary Hyperoxaluria Type 3 | Primary Hyperoxaluria Type 2 | Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Canada, Lebanon, Turkey, United Kingdom, Germany, Italy, Japan, Poland, Spain, United Arab Emirates
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Phase 1b Study of DCR-AUD in Healthy Volunteers

Alcohol Use Disorder

United States
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Active, not recruiting

Natural History of Patients With PH3 and a History of Stone Events (PHYOX-OBX)

Primary Hyperoxaluria Type 3

United States, Germany, United Kingdom, Canada, Poland
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Study of DCR-A1AT in Healthy Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand, Sweden
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Enrolling by invitation

Long Term Extension Study in Patients With Primary Hyperoxaluria (PHYOX3)

Kidney Diseases | Urologic Diseases | Genetic Disease | Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria Type 2 (PH2) | Primary Hyperoxaluria Type 3 (PH3)

United States, France, Germany, Japan, Lebanon, Spain, United Kingdom, Australia, Canada, Italy, Netherlands, Norway, Turkey
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Available

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

Primary Hyperoxaluria Type 1 (PH1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Recruiting

A Study of DCR-STAT3 in Adults With Solid Tumors

Solid Tumor, Adult | Refractory Tumor

United States
Nobel Pharmaceuticals
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

Completed

Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease

Behcet Syndrome | Behcet Disease | Mucocutaneous Ulceration

Turkey
Alexion Pharmaceuticals, Inc.
Eidos Therapeutics, a BridgeBio company

Active, not recruiting

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Symptomatic Transthyretin Amyloid Cardiomyopathy

Japan
NeuroBo Pharmaceuticals Inc.
Dong-A ST Co., Ltd.

Completed

Study of DA-9801 to Treat Diabetic Neuropathy

Diabetic Neuropathy

United States
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)

Terminated

Study Evaluating Betrixaban in Pediatric Participants

VTE Prophylaxis

United States, United Kingdom, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S; Otsuka America Pharmaceutical

Completed

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

Schizophrenia

United States, Croatia, Latvia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer's Disease

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Alzheimer Dementia | Agitation Associated With Alzheimer's Dementia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Active, not recruiting

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Irritability Associated With Autism Spectrum Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Withdrawn

Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety

Major Depressive Disorder (MDD)
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

Spain, United States, Germany, Croatia, Serbia, Russian Federation, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.

Bipolar I Disorder | Acute Mania

United States, Serbia, Bulgaria, Croatia, Poland, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

United States, Croatia, Ukraine
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder | Manic Episode

Serbia, United States, Bulgaria, Poland
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

Nervous System Diseases | Mental Disorder | Alzheimer's Type | Agitation Associated With Alzheimer's Disease

United States, Germany, France, Bulgaria, Spain, Slovenia, Croatia, Serbia, Russian Federation, Ukraine, Canada, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder (Anchor)

Irritability Associated With Autism Spectrum Disorder (ASD)

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Stress Disorders, Post-Traumatic

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Nervous System Diseases | Alzheimer's Disease | Mental Disorder | Agitation Associated With | Alzheimer's Type

France, United States, Bulgaria, Slovenia, United Kingdom, Russian Federation, Ukraine, Finland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (ATLAS)

Bipolar I

United States, France, Romania, Poland, Canada, Hungary, Japan, Korea, Republic of, Malaysia, Taiwan
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

Bipolar I Disorder

United States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

Mental Disorders | Depressive Disorder | Depression | Mood Disorders | Depressive Disorder, Major

United States, Germany, Poland, Hungary, Slovakia
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders

ADHD | Conduct Disorder | Oppositional Defiant Disorder | Autism | Bipolar I Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Terminated

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Schizophrenia

United States
Otsuka Pharmaceutical Development & Commercialization...
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Nervous System Diseases | Schizophrenia | Mental Disorder

United States

Clinical Trials Sponsored by A&G Pharmaceutical Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations